Sign In
Buy LOBEF
$0.0540
-0.0110 (-16.91%)
At Close: Jul 31, 2026
Lobe Sciences enters into exclusive agreement with contract research organization iNGENū to conduct clinical trials in Australia
10:23am, Wednesday, 10'th Aug 2022
Lobe Sciences Ltd (CSE:LOBE, OTCQB:LOBED) has announced that it has entered into an exclusive research agreement with Australian-based contract research organization (CRO) iNGENū Pty Ltd to design an
Lobe Sciences files patent for preparation of stable psilocin prodrugs and analogues
08:19am, Tuesday, 19'th Jul 2022
Lobe Sciences Ltd (CSE:LOBE, OTCQB:LOBED) said it has filed a provisional patent for the preparation and use of its proprietary and stable psilocin-related compounds. In a statement, Philip Young, C
Lobe Sciences Ltd (CSE:LOBE, OTCQB:LOBED) has announced the development of its initial Phase 1 study plan to demonstrate the safety and appropriate dosing range for its proprietary new chemical entity
Lobe Sciences Ltd. to Participate in the Lytham Partners Spring 2022 Investor Conference
08:09am, Wednesday, 30'th Mar 2022
Vancouver, British Columbia--(Newsfile Corp. - March 30, 2022) - Lobe Sciences Ltd. (CSE: LOBE) (OTCQB: LOBEF) ("Lobe" or the "Company") announced today that it will be participating in the Lytham Par
